Molecular diagnostics of gliomas: State of the art

Acta Neuropathologica

Volumn 120, Issue 5, 2010, Pages 567-584

  Riemenschneider, Markus J ^a   Jeuken, Judith W M ^b   Wesseling, Pieter ^b   Reifenberger, Guido ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

1p 19q deletion; BRAF duplication; Glioma; IDH1 mutation; MGMT promoter methylation; Molecular diagnostics

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; B RAF KINASE; CARMUSTINE; EPIDERMAL GROWTH FACTOR RECEPTOR; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE ISOENZYME; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MOLECULAR MARKER; NITROSOUREA; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ASTROCYTOMA; ASTROCYTOSIS; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER RISK; CANCER SURVIVAL; CANCER TEST; CHILDHOOD CANCER; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME DELETION; CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; EPENDYMOMA; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC ASSOCIATION; GENETIC EPIGENESIS; GLIOBLASTOMA; GLIOMA; HETEROZYGOSITY LOSS; HUMAN; MOLECULAR DYNAMICS; MOLECULAR TYPING; OLIGODENDROGLIOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN METHYLATION; REVIEW; SENSITIVITY AND SPECIFICITY;

BRAIN NEOPLASMS; EPIGENOMICS; GLIOMA; HUMANS; MOLECULAR BIOLOGY; PATHOLOGY, MOLECULAR;

EID: 78149405879     PISSN: 00016322     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00401-010-0736-4     Document Type: Review

References (141)

1. Antonelli M, Buttarelli FR, Arcella A, Nobusawa S, Donofrio V, Oghaki H and Giangaspero F (2010) Prognostic significance of histological grading, p53 status, YKL-40 expression, and IDH1 mutations in pediatric high-grade gliomas. J Neurooncol [Epub ahead of print]
2. J Balss J Meyer W Mueller A Korshunov C Hartmann A von Deimling 2008 Analysis of the IDH1 codon 132 mutation in brain tumors Acta Neuropathol 116 597 602 1:CAS:528:DC%2BD1cXhtlyhsbfN 18985363
3. EE Bar A Lin T Tihan PC Burger CG Eberhart 2008 Frequent gains at chromosome 7q34 involving BRAF in pilocytic astrocytoma J Neuropathol Exp Neurol 67 878 887 1:CAS:528:DC%2BD1cXhtFKisb3P 18716556
4. FG Barker 2nd ML Simmons SM Chang MD Prados DA Larson PK Sneed WM Wara MS Berger P Chen MA Israel KD Aldape 2001 EGFR overexpression and radiation response in glioblastoma multiforme Int J Radiat Oncol Biol Phys 51 410 418 1:CAS:528:DC%2BD3MXmvVyltb0%3D 11567815
5. JP Bayley P Devilee 2010 Warburg tumours and the mechanisms of mitochondrial tumour suppressor genes. Barking up the right tree? Curr Opin Genet Dev 20 324 329 1:CAS:528:DC%2BC3cXntlCru7k%3D 20304625
6. D Beier P Hau M Proescholdt A Lohmeier J Wischhusen PJ Oefner L Aigner A Brawanski U Bogdahn CP Beier 2007 CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles Cancer Res 67 4010 4015 1:CAS:528:DC%2BD2sXltVyku74%3D 17483311
7. M Belanich M Pastor T Randall D Guerra J Kibitel L Alas B Li M Citron P Wasserman A White H Eyre K Jaeckle S Schulman D Rector M Prados S Coons W Shapiro D Yarosh 1996 Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine Cancer Res 56 783 788 1:CAS:528:DyaK28XhtVClsLc%3D 8631014
8. FE Bleeker S Lamba S Leenstra D Troost T Hulsebos WP Vandertop M Frattini F Molinari M Knowles A Cerrato M Rodolfo A Scarpa L Felicioni F Buttitta S Malatesta A Marchetti A Bardelli 2009 IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors Hum Mutat 30 7 11 1:CAS:528:DC%2BD1MXivFygs7g%3D 19117336
9. AA Brandes L Nicolardi A Tosoni M Gardiman P Iuzzolino C Ghimenton M Reni A Rotilio G Sotti M Ermani 2006 Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma Neuro Oncol 8 253 260 1:CAS:528:DC%2BD28Xot1agtLo%3D 16723632
10. DJ Brat AA Castellano-Sanchez SB Hunter M Pecot C Cohen EH Hammond SN Devi B Kaur EG Van Meir 2004 Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population Cancer Res 64 920 927 1:CAS:528:DC%2BD2cXhtFCgtbk%3D 14871821
11. DJ Brat EG Van Meir 2004 Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma Lab Invest 84 397 405 1:CAS:528:DC%2BD2cXmtF2itrw%3D 14990981
12. Brokinkel B, Fischer BR, Peetz-Dienhart S, Ebel H, Sepehrnia A, Rama B, Albert FK, Stummer W, Paulus W and Hasselblatt M (2010) MGMT promoter methylation status in anaplastic meningiomas. J Neurooncol [Epub ahead of print]
13. AM Buccoliero F Castiglione D Rossi Degl'Innocenti M Paglierani V Maio CF Gheri F Garbini D Moncini A Taddei I Sardi M Sanzo F Giordano F Mussa L Genitori GL Taddei 2008 O6-Methylguanine-DNA-methyltransferase in recurring anaplastic ependymomas: PCR and immunohistochemistry J Chemother 20 263 268 1:CAS:528:DC%2BD1cXnvVansr4%3D 18467255
14. M Bujko P Kober E Matyja P Nauman K Dyttus-Cebulok B Czeremszynska W Bonicki JA Siedlecki 2010 Prognostic value of IDH1 mutations identified with PCR-RFLP assay in glioblastoma patients Mol Diagn Ther 14 163 169 1:CAS:528:DC%2BC3cXhtVGls7bO 20560678
15. DP Cahill KK Levine RA Betensky PJ Codd CA Romany LB Reavie TT Batchelor PA Futreal MR Stratton WT Curry AJ Iafrate DN Louis 2007 Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment Clin Cancer Res 13 2038 2045 1:CAS:528: DC%2BD2sXjs12rtrs%3D 17404084
16. G Cairncross B Berkey E Shaw R Jenkins B Scheithauer D Brachman J Buckner K Fink L Souhami N Laperierre M Mehta W Curran 2006 Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402 J Clin Oncol 24 2707 2714 1:CAS:528:DC%2BD28XntV2hurg%3D 16782910
17. JG Cairncross K Ueki MC Zlatescu DK Lisle DM Finkelstein RR Hammond JS Silver PC Stark DR Macdonald Y Ino DA Ramsay DN Louis 1998 Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas J Natl Cancer Inst 90 1473 1479 1:STN:280: DyaK1cvkslejug%3D%3D 9776413
18. Cancer Genome Atlas Research Network 2008 Comprehensive genomic characterization defines human glioblastoma genes and core pathways Nature 455 1061 1068
19. D Capper S Weissert J Balss A Habel J Meyer D Jager U Ackermann C Tessmer A Korshunov H Zentgraf C Hartmann A von Deimling 2010 Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors Brain Pathol 20 245 254 1:CAS:528:DC%2BC3cXpvFOlsA%3D%3D 19903171
20. A Chakravarti A Chakladar MA Delaney DE Latham JS Loeffler 2002 The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner Cancer Res 62 4307 4315 1:CAS:528: DC%2BD38XlvFeltbY%3D 12154034
21. CL Cheng SP Johnson ST Keir JA Quinn F Ali-Osman C Szabo H Li AL Salzman ME Dolan P Modrich DD Bigner HS Friedman 2005 Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft Mol Cancer Ther 4 1364 1368 1:CAS:528: DC%2BD2MXhtVKnt7nP 16170028
22. OL Chinot M Barrie S Fuentes N Eudes S Lancelot P Metellus X Muracciole D Braguer L Ouafik PM Martin H Dufour D Figarella-Branger 2007 Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide J Clin Oncol 25 1470 1475 1:CAS:528:DC%2BD2sXlsVyntbo%3D 17442989
23. WC Chou HA Hou CY Chen JL Tang M Yao W Tsay BS Ko SJ Wu SY Huang SC Hsu YC Chen YN Huang YC Chang FY Lee MC Liu CW Liu MH Tseng CF Huang HF Tien 2010 Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation Blood 115 2749 2754 1:CAS:528:DC%2BC3cXkvFKiurY%3D 20097881
24. A Claes AJ Idema P Wesseling 2007 Diffuse glioma growth: a guerilla war Acta Neuropathol 114 443 458 17805551
25. H Colman L Zhang EP Sulman JM McDonald NL Shooshtari A Rivera S Popoff CL Nutt DN Louis JG Cairncross MR Gilbert HS Phillips MP Mehta A Chakravarti CE Pelloski K Bhat BG Feuerstein RB Jenkins K Aldape 2010 A multigene predictor of outcome in glioblastoma Neuro Oncol 12 49 57 1:CAS:528:DC%2BC3cXjvFCnt7c%3D 20150367
26. L Dang DW White S Gross BD Bennett MA Bittinger EM Driggers VR Fantin HG Jang S Jin MC Keenan KM Marks RM Prins PS Ward KE Yen LM Liau JD Rabinowitz LC Cantley CB Thompson MG Vander Heiden SM Su 2009 Cancer-associated IDH1 mutations produce 2-hydroxyglutarate Nature 462 739 744 1:CAS:528:DC%2BD1MXhsVGlurzE 19935646
27. C Dehais F Laigle-Donadey Y Marie M Kujas J Lejeune A Benouaich-Amiel M Pedretti M Polivka KH Xuan J Thillet JY Delattre M Sanson 2006 Prognostic stratification of patients with anaplastic gliomas according to genetic profile Cancer 107 1891 1897 1:CAS:528:DC%2BD28Xht1Cms7fI 16986124
28. S Delic N Schmidt N Lottmann A Stefanski K Stuhler G Reifenberger MJ Riemenschneider 2009 In vivo and in vitro selection of infiltrating glioma cells: a comprehensive, multi-dimensional molecular analysis of the invasive phenotype of human glioblastomas Acta Neuropathol 118 437 437 (Meeting Abstract)
29. S Dong CL Nutt RA Betensky AO Stemmer-Rachamimov NC Denko KL Ligon DH Rowitch DN Louis 2005 Histology-based expression profiling yields novel prognostic markers in human glioblastoma J Neuropathol Exp Neurol 64 948 955 16254489
30. HJ Dubbink W Taal R van Marion JM Kros I van Heuvel JE Bromberg BA Zonnenberg CB Zonnenberg TJ Postma JM Gijtenbeek W Boogerd FH Groenendijk PA Smitt WN Dinjens MJ van den Bent 2009 IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide Neurology 73 1792 1795 1:CAS:528:DC%2BD1MXhsVaks77K 19933982
31. M Ebinger L Senf O Wachowski W Scheurlen 2004 Promoter methylation pattern of caspase-8, P16INK4A, MGMT, TIMP-3, and E-cadherin in medulloblastoma Pathol Oncol Res 10 17 21 1:CAS:528:DC%2BD2cXktlCiu7s%3D 15029256
32. M Esteller J Garcia-Foncillas E Andion SN Goodman OF Hidalgo V Vanaclocha SB Baylin JG Herman 2000 Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents N Engl J Med 343 1350 1354 1:CAS:528:DC%2BD3cXosFOltLg%3D 11070098
33. J Felsberg A Erkwoh MC Sabel L Kirsch R Fimmers B Blaschke U Schlegel J Schramm OD Wiestler G Reifenberger 2004 Oligodendroglial tumors: refinement of candidate regions on chromosome arm 1p and correlation of 1p/19q status with survival Brain Pathol 14 121 130 1:CAS:528:DC%2BD2cXkvFCgs7Y%3D 15193024
34. J Felsberg M Rapp S Loeser R Fimmers W Stummer M Goeppert HJ Steiger B Friedensdorf G Reifenberger MC Sabel 2009 Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients Clin Cancer Res 15 6683 6693 1:CAS:528:DC%2BD1MXhtlCjsrfP 19861461
35. J Felsberg M Wolter H Seul B Friedensdorf M Goppert MC Sabel G Reifenberger 2010 Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing Acta Neuropathol 119 501 507 1:CAS:528:DC%2BC3cXjs1aisr8%3D 20131059
36. Y Fu R Huang J Du R Yang N An A Liang 2010 Glioma-derived mutations in IDH: from mechanism to potential therapy Biochem Biophys Res Commun 397 127 130 1:CAS:528:DC%2BC3cXotVChtbk%3D 20510884
37. J Gaal N Burnichon E Korpershoek I Roncelin J Bertherat PF Plouin RR de Krijger AP Gimenez-Roqueplo WN Dinjens 2010 Isocitrate dehydrogenase mutations are rare in pheochromocytomas and paragangliomas J Clin Endocrinol Metab 95 1274 1278 1:CAS:528:DC%2BC3cXjs1Kqt7k%3D 19915015
38. HK Gan AH Kaye RB Luwor 2009 The EGFRvIII variant in glioblastoma multiforme J Clin Neurosci 16 748 754 1:CAS:528:DC%2BD1MXltl2lu7o%3D 19324552
39. SL Gerson 2004 MGMT: its role in cancer aetiology and cancer therapeutics Nat Rev Cancer 4 296 307 1:CAS:528:DC%2BD2cXis1Gmt70%3D 15057289
40. C Giannini PC Burger BA Berkey JG Cairncross RB Jenkins M Mehta WJ Curran K Aldape 2008 Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402 Brain Pathol 18 360 369 18371182
41. LA Gravendeel NK Kloosterhof LB Bralten R van Marion HJ Dubbink W Dinjens FE Bleeker CC Hoogenraad E Michiels JM Kros M van den Bent PA Smitt PJ French 2010 Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma Hum Mutat 31 E1186 E1199 1:CAS:528:DC%2BC3cXktVOns74%3D 20077503
42. CA Griffin P Burger L Morsberger R Yonescu S Swierczynski JD Weingart KM Murphy 2006 Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss J Neuropathol Exp Neurol 65 988 994 17021403
43. S Gross RA Cairns MD Minden EM Driggers MA Bittinger HG Jang M Sasaki S Jin DP Schenkein SM Su L Dang VR Fantin TW Mak 2010 Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations J Exp Med 207 339 344 1:CAS:528: DC%2BC3cXitFGqur0%3D 20142433
44. DA Haas-Kogan MD Prados T Tihan DA Eberhard N Jelluma ND Arvold R Baumber KR Lamborn A Kapadia M Malec MS Berger D Stokoe 2005 Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib J Natl Cancer Inst 97 880 887 1:CAS:528:DC%2BD2MXmtVahtrs%3D 15956649
45. ME Halatsch U Schmidt J Behnke-Mursch A Unterberg CR Wirtz 2006 Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours Cancer Treat Rev 32 74 89 1:CAS:528: DC%2BD28XisFOqtL8%3D 16488082
46. C Hartmann J Meyer J Balss D Capper W Mueller A Christians J Felsberg M Wolter C Mawrin W Wick M Weller C Herold-Mende A Unterberg JW Jeuken P Wesseling G Reifenberger A von Deimling 2009 Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas Acta Neuropathol 118 469 474 19554337
47. KJ Hatanpaa PC Burger JR Eshleman KM Murphy KD Berg 2003 Molecular diagnosis of oligodendroglioma in paraffin sections Lab Invest 83 419 428 1:CAS:528:DC%2BD3sXhvF2qurs%3D 12649342
48. ME Hegi AC Diserens T Gorlia MF Hamou N de Tribolet M Weller JM Kros JA Hainfellner W Mason L Mariani JE Bromberg P Hau RO Mirimanoff JG Cairncross RC Janzer R Stupp 2005 MGMT gene silencing and benefit from temozolomide in glioblastoma N Engl J Med 352 997 1003 1:CAS:528:DC%2BD2MXit1Wktro%3D 15758010
49. AB Heimberger LE Crotty GE Archer KR Hess CJ Wikstrand AH Friedman HS Friedman DD Bigner JH Sampson 2003 Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors Clin Cancer Res 9 4247 4254 1:CAS:528:DC%2BD3sXns1Ojuro%3D 14519652
50. AB Heimberger R Hlatky D Suki D Yang J Weinberg M Gilbert R Sawaya K Aldape 2005 Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients Clin Cancer Res 11 1462 1466 1:CAS:528:DC%2BD2MXhvVSrsb4%3D 15746047
51. AB Heimberger JH Sampson 2009 The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients Expert Opin Biol Ther 9 1087 1098 1:CAS:528:DC%2BD1MXotlOksr0%3D 19591631
52. JG Herman JR Graff S Myohanen BD Nelkin SB Baylin 1996 Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands Proc Natl Acad Sci USA 93 9821 9826 1:CAS:528:DyaK28XlsFeht7Y%3D 8790415
53. U Herrlinger J Rieger D Koch S Loeser B Blaschke RD Kortmann JP Steinbach T Hundsberger W Wick R Meyermann TC Tan C Sommer M Bamberg G Reifenberger M Weller 2006 Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03 J Clin Oncol 24 4412 4417 16983109
54. DB Hoelzinger L Mariani J Weis T Woyke TJ Berens WS McDonough A Sloan SW Coons ME Berens 2005 Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets Neoplasia 7 7 16 1:CAS:528:DC%2BD2MXit1Gnsb8%3D 15720813
55. C Horbinski L Kelly YE Nikiforov MB Durso MN Nikiforova 2010 Detection of IDH1 and IDH2 mutations by fluorescence melting curve analysis as a diagnostic tool for brain biopsies J Mol Diagn 12 487 492 1:CAS:528:DC%2BC3cXhtVehurrF 20431032
56. C Horbinski J Kofler LM Kelly GH Murdoch MN Nikiforova 2009 Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues J Neuropathol Exp Neurol 68 1319 1325 1:CAS:528:DC%2BD1MXhsVOhtLvE 19915484
57. C Hunter R Smith DP Cahill P Stephens C Stevens J Teague C Greenman S Edkins G Bignell H Davies S O'Meara A Parker T Avis S Barthorpe L Brackenbury G Buck A Butler J Clements J Cole E Dicks S Forbes M Gorton K Gray K Halliday R Harrison K Hills J Hinton A Jenkinson D Jones V Kosmidou R Laman R Lugg A Menzies J Perry R Petty K Raine D Richardson R Shepherd A Small H Solomon C Tofts J Varian S West S Widaa A Yates DF Easton G Riggins JE Roy KK Levine W Mueller TT Batchelor DN Louis MR Stratton PA Futreal R Wooster 2006 A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy Cancer Res 66 3987 3991 1:CAS:528:DC%2BD28XjsFSlsbw%3D 16618716
58. K Ichimura DM Pearson S Kocialkowski LM Backlund R Chan DT Jones VP Collins 2009 IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas Neuro Oncol 11 341 347 1:CAS:528: DC%2BD1MXhtV2qur%2FF 19435942
59. Y Ino RA Betensky MC Zlatescu H Sasaki DR Macdonald AO Stemmer-Rachamimov DA Ramsay JG Cairncross DN Louis 2001 Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis Clin Cancer Res 7 839 845 1:STN:280:DC%2BD3M3pvFGqtw%3D%3D 11309331
60. International Cancer Genome Consortium 2010 International network of cancer genome projects Nature 464 993 998
61. KA Jaeckle HJ Eyre JJ Townsend S Schulman HM Knudson M Belanich DB Yarosh SI Bearman DJ Giroux SC Schold 1998 Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study J Clin Oncol 16 3310 3315 1:CAS:528:DyaK1cXmvFGrtbw%3D 9779706
62. RB Jenkins H Blair KV Ballman C Giannini RM Arusell M Law H Flynn S Passe S Felten PD Brown EG Shaw JC Buckner 2006 A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma Cancer Res 66 9852 9861 1:CAS:528:DC%2BD28XhtVyiur3I 17047046
63. J Jeuken S Cornelissen S Boots-Sprenger S Gijsen P Wesseling 2006 Multiplex ligation-dependent probe amplification: a diagnostic tool for simultaneous identification of different genetic markers in glial tumors J Mol Diagn 8 433 443 1:CAS:528:DC%2BD28XpvFClurw%3D 16931583
64. J Jeuken A Sijben C Alenda J Rijntjes M Dekkers S Boots-Sprenger R McLendon P Wesseling 2009 Robust detection of EGFR copy number changes and EGFR variant III: technical aspects and relevance for glioma diagnostics Brain Pathol 19 661 671 19744038
65. JW Jeuken SJ Cornelissen M Vriezen MM Dekkers A Errami A Sijben SH Boots-Sprenger P Wesseling 2007 MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas Lab Invest 87 1055 1065 1:CAS:528:DC%2BD2sXhtVCrtLjF 17700563
66. JW Jeuken SH Sprenger RH Boerman A von Deimling HL Teepen JJ van Overbeeke P Wesseling 2001 Subtyping of oligo-astrocytic tumours by comparative genomic hybridization J Pathol 194 81 87 1:CAS:528:DC%2BD3MXjvVahtbs%3D 11329145
67. JW Jeuken SH Sprenger P Wesseling MV Macville A von Deimling HL Teepen JJ van Overbeeke RH Boerman 1999 Identification of subgroups of high-grade oligodendroglial tumors by comparative genomic hybridization J Neuropathol Exp Neurol 58 606 612 1:CAS:528:DyaK1MXktVaqt7g%3D 10374751
68. JW Jeuken A von Deimling P Wesseling 2004 Molecular pathogenesis of oligodendroglial tumors J Neurooncol 70 161 181 15674476
69. DT Jones S Kocialkowski L Liu DM Pearson LM Backlund K Ichimura VP Collins 2008 Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas Cancer Res 68 8673 8677 1:CAS:528:DC%2BD1cXhtlSktbfM 18974108
70. DT Jones S Kocialkowski L Liu DM Pearson K Ichimura VP Collins 2009 Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma Oncogene 28 2119 2123 1:CAS:528:DC%2BD1MXksVeluro%3D 19363522
71. MR Kang MS Kim JE Oh YR Kim SY Song SI Seo JY Lee NJ Yoo SH Lee 2009 Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers Int J Cancer 125 353 355 1:CAS:528:DC%2BD1MXms1amu70%3D 19378339
72. Y Kato G Jin CT Kuan RE McLendon H Yan DD Bigner 2009 A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation Biochem Biophys Res Commun 390 547 551 1:CAS:528:DC%2BD1MXhsVKgtLfO 19818334
73. P Kleihues H Ohgaki 1999 Primary and secondary glioblastomas: from concept to clinical diagnosis Neuro-oncol 1 44 51 1:STN:280: DC%2BD3MrgtFCktg%3D%3D 11550301
74. B Koos S Peetz-Dienhart B Riesmeier MC Fruhwald M Hasselblatt 2010 O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation is significantly less frequent in ependymal tumours as compared to malignant astrocytic gliomas Neuropathol Appl Neurobiol 36 356 358 1:CAS:528: DC%2BC3cXot1artL0%3D 20202118
75. A Korshunov J Meyer D Capper A Christians M Remke H Witt S Pfister A von Deimling C Hartmann 2009 Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma Acta Neuropathol 118 401 405 1:CAS:528:DC%2BD1MXptVGjt7c%3D 19543740
76. A Korshunov H Witt T Hielscher A Benner M Remke M Ryzhova T Milde S Bender A Wittmann A Schottler AE Kulozik O Witt A von Deimling P Lichter S Pfister 2010 Molecular staging of intracranial ependymoma in children and adults J Clin Oncol 28 3182 3190 20516456
77. M Labussiere A Idbaih XW Wang Y Marie B Boisselier C Falet S Paris J Laffaire C Carpentier E Criniere F Ducray S El Hallani K Mokhtari K Hoang-Xuan JY Delattre M Sanson 2010 All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2 Neurology 74 1886 1890 1:CAS:528:DC%2BC3cXntF2gtbw%3D 20427748
78. N Levin I Lavon B Zelikovitsh D Fuchs F Bokstein Y Fellig T Siegal 2006 Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression Cancer 106 1759 1765 1:CAS:528:DC%2BD28XksFCku7Y%3D 16541434
79. G Li AJ Wong 2008 EGF receptor variant III as a target antigen for tumor immunotherapy Expert Rev Vaccines 7 977 985 18767947
80. U Linz 2010 Commentary on Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial (Lancet Oncol. 2009;10:459-466) Cancer 116 1844 1846 20151424
81. Louis DN, Ohgaki H, Wiestler OD, CaveneeWK (eds) (2007) WHO classification of tumours of the central nervous system, 3rd edn. IARC Press, Lyon
82. JA Maxwell SP Johnson RE McLendon DW Lister KS Horne A Rasheed JA Quinn F Ali-Osman AH Friedman PL Modrich DD Bigner HS Friedman 2008 Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma Clin Cancer Res 14 4859 4868 1:CAS:528:DC%2BD1cXpt1ejurk%3D 18676759
83. KL McDonald J McDonnell A Muntoni JD Henson ME Hegi A von Deimling HR Wheeler RJ Cook MT Biggs NS Little BG Robinson RR Reddel JA Royds 2010 Presence of alternative lengthening of telomeres mechanism in patients with glioblastoma identifies a less aggressive tumor type with longer survival J Neuropathol Exp Neurol 69 729 736 20535033
84. B McEllin CV Camacho B Mukherjee B Hahm N Tomimatsu RM Bachoo S Burma 2010 PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors Cancer Res 70 5457 5464 1:CAS:528:DC%2BC3cXot1Wks7w%3D 20530668
85. IK Mellinghoff MY Wang I Vivanco DA Haas-Kogan S Zhu EQ Dia KV Lu K Yoshimoto JH Huang DJ Chute BL Riggs S Horvath LM Liau WK Cavenee PN Rao R Beroukhim TC Peck JC Lee WR Sellers D Stokoe M Prados TF Cloughesy CL Sawyers PS Mischel 2005 Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors N Engl J Med 353 2012 2024 1:CAS:528:DC%2BD2MXht1SrtrrE 16282176
86. J Meyer S Pusch J Balss D Capper W Mueller A Christians C Hartmann A von Deimling 2010 PCR- and restriction endonuclease-based detection of IDH1 mutations Brain Pathol 20 298 300 1:CAS:528:DC%2BC3cXjs1Ggsbg%3D 19744125
87. T Mikeska C Bock O El-Maarri A Hubner D Ehrentraut J Schramm J Felsberg P Kahl R Buttner T Pietsch A Waha 2007 Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis J Mol Diagn 9 368 381 1:CAS:528:DC%2BD2sXot1Kqsrc%3D 17591937
88. M Mollemann M Wolter J Felsberg VP Collins G Reifenberger 2005 Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors Int J Cancer 113 379 385 15455350
89. A Murat E Migliavacca T Gorlia WL Lambiv T Shay MF Hamou N de Tribolet L Regli W Wick MC Kouwenhoven JA Hainfellner FL Heppner PY Dietrich Y Zimmer JG Cairncross RC Janzer E Domany M Delorenzi R Stupp ME Hegi 2008 Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma J Clin Oncol 26 3015 3024 1:CAS:528:DC%2BD1cXoslOqsLs%3D 18565887
90. S Nobusawa T Watanabe P Kleihues H Ohgaki 2009 IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas Clin Cancer Res 15 6002 6007 1:CAS:528:DC%2BD1MXhtF2ltbbL 19755387
91. H Noushmehr DJ Weisenberger K Diefes HS Phillips K Pujara BP Berman F Pan CE Pelloski EP Sulman KP Bhat RG Verhaak KA Hoadley DN Hayes CM Perou HK Schmidt L Ding RK Wilson D Van Den Berg H Shen H Bengtsson P Neuvial LM Cope J Buckley JG Herman SB Baylin PW Laird K Aldape 2010 Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma Cancer Cell 17 510 522 1:CAS:528:DC%2BC3cXmslKqsr0%3D 20399149
92. CL Nutt DR Mani RA Betensky P Tamayo JG Cairncross C Ladd U Pohl C Hartmann ME McLaughlin TT Batchelor PM Black A von Deimling SL Pomeroy TR Golub DN Louis 2003 Gene expression-based classification of malignant gliomas correlates better with survival than histological classification Cancer Res 63 1602 1607 1:CAS:528:DC%2BD3sXisFaitbc%3D 12670911
93. H Ohgaki P Kleihues 2007 Genetic pathways to primary and secondary glioblastoma Am J Pathol 170 1445 1453 1:CAS:528:DC%2BD2sXlvFCns74%3D 17456751
94. R Papait L Magrassi D Rigamonti E Cattaneo 2009 Temozolomide and carmustine cause large-scale heterochromatin reorganization in glioma cells Biochem Biophys Res Commun 379 434 439 1:CAS:528:DC%2BD1MXotl2itg%3D%3D 19116135
95. DW Parsons S Jones X Zhang JC Lin RJ Leary P Angenendt P Mankoo H Carter IM Siu GL Gallia A Olivi R McLendon BA Rasheed S Keir T Nikolskaya Y Nikolsky DA Busam H Tekleab LA Diaz Jr J Hartigan DR Smith RL Strausberg SK Marie SM Shinjo H Yan GJ Riggins DD Bigner R Karchin N Papadopoulos G Parmigiani B Vogelstein VE Velculescu KW Kinzler 2008 An integrated genomic analysis of human glioblastoma multiforme Science 321 1807 1812 1:CAS:528:DC%2BD1cXhtFCrtLrE 18772396
96. BS Paugh C Qu C Jones Z Liu M Adamowicz-Brice J Zhang DA Bax B Coyle J Barrow D Hargrave J Lowe A Gajjar W Zhao A Broniscer DW Ellison RG Grundy SJ Baker 2010 Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease J Clin Oncol 28 3061 3068 20479398
97. CE Pelloski KV Ballman AF Furth L Zhang E Lin EP Sulman K Bhat JM McDonald WK Yung H Colman SY Woo AB Heimberger D Suki MD Prados SM Chang FG Barker 2nd JC Buckner CD James K Aldape 2007 Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma J Clin Oncol 25 2288 2294 1:CAS:528:DC%2BD2sXnsVShu78%3D 17538175
98. S Pfister WG Janzarik M Remke A Ernst W Werft N Becker G Toedt A Wittmann C Kratz H Olbrich R Ahmadi B Thieme S Joos B Radlwimmer A Kulozik T Pietsch C Herold-Mende A Gnekow G Reifenberger A Korshunov W Scheurlen H Omran P Lichter 2008 BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas J Clin Invest 118 1739 1749 1:CAS:528: DC%2BD1cXlsF2ntLY%3D 18398503
99. HS Phillips S Kharbanda R Chen WF Forrest RH Soriano TD Wu A Misra JM Nigro H Colman L Soroceanu PM Williams Z Modrusan BG Feuerstein K Aldape 2006 Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis Cancer Cell 9 157 173 1:CAS:528:DC%2BD28XivFWjtL4%3D 16530701
100. IF Pollack RL Hamilton RW Sobol J Burnham AJ Yates EJ Holmes T Zhou JL Finlay 2006 O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 cohort J Clin Oncol 24 3431 3437 1:CAS:528:DC%2BD28Xot1KisLo%3D 16849758
101. M Preusser E Gelpi A Rottenfusser K Dieckmann G Widhalm W Dietrich A Bertalanffy D Prayer JA Hainfellner C Marosi 2008 Epithelial growth factor receptor inhibitors for treatment of recurrent or progressive high grade glioma: an exploratory study J Neurooncol 89 211 218 1:STN:280:DC%2BD1cvovVWjug%3D%3D 18458820
102. G Reifenberger DN Louis 2003 Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology J Neuropathol Exp Neurol 62 111 126 1:CAS:528:DC%2BD3sXhsFaiurs%3D 12578221
103. ZJ Reitman H Yan 2010 Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism J Natl Cancer Inst 102 932 941 1:CAS:528:DC%2BC3cXptlegs7c%3D 20513808
104. AL Rivera CE Pelloski MR Gilbert H Colman C De La Cruz EP Sulman BN Bekele KD Aldape 2010 MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma Neuro Oncol 12 116 121 1:CAS:528:DC%2BC3cXotFKitb8%3D 20150378
105. P Roerig M Nessling B Radlwimmer S Joos G Wrobel C Schwaenen G Reifenberger P Lichter 2005 Molecular classification of human gliomas using matrix-based comparative genomic hybridization Int J Cancer 117 95 103 1:CAS:528:DC%2BD2MXhtVaht7vO 15880582
106. Rokes CA, Remke M, Guha-Thakurta N, Witt O, Korshunov A, Pfister S and Wolff JE (2010) Sorafenib plus valproic acid for infant spinal glioblastoma. J Pediatr Hematol Oncol
107. JH Sampson GE Archer DA Mitchell AB Heimberger DD Bigner 2008 Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma Semin Immunol 20 267 275 1:CAS:528:DC%2BD1cXhtlyhtbfL 18539480
108. M Sanson Y Marie S Paris A Idbaih J Laffaire F Ducray S El Hallani B Boisselier K Mokhtari K Hoang-Xuan JY Delattre 2009 Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas J Clin Oncol 27 4150 4154 1:CAS:528:DC%2BD1MXhtF2jtLrP 19636000
109. D Scheie M Cvancarova S Mork K Skullerud PA Andresen I Benestad E Helseth T Meling K Beiske 2008 Can morphology predict 1p/19q loss in oligodendroglial tumours? Histopathology 53 578 587 1:STN:280:DC%2BD1cjhvVahsA%3D%3D 18983467
110. S Schlosser S Wagner J Muhlisch M Hasselblatt J Gerss JE Wolff MC Fruhwald 2010 MGMT as a potential stratification marker in relapsed high-grade glioma of children: the HIT-GBM experience Pediatr Blood Cancer 54 228 237 19856394
111. JP Schouten CJ McElgunn R Waaijer D Zwijnenburg F Diepvens G Pals 2002 Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification Nucleic Acids Res 30 e57 12060695
112. M Seiz J Tuettenberg J Meyer M Essig K Schmieder C Mawrin A von Deimling C Hartmann 2010 Detection of IDH1 mutations in gliomatosis cerebri, but only in tumors with additional solid component: evidence for molecular subtypes Acta Neuropathol 120 261 267 1:CAS:528:DC%2BC3cXotVKnsbo%3D 20514489
113. N Shinojima K Tada S Shiraishi T Kamiryo M Kochi H Nakamura K Makino H Saya H Hirano J Kuratsu K Oka Y Ishimaru Y Ushio 2003 Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme Cancer Res 63 6962 6970 1:CAS:528:DC%2BD3sXosVGnsLg%3D 14583498
114. JS Smith B Alderete Y Minn TJ Borell A Perry G Mohapatra SM Hosek D Kimmel J O'Fallon A Yates BG Feuerstein PC Burger BW Scheithauer RB Jenkins 1999 Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype Oncogene 18 4144 4152 1:CAS:528:DyaK1MXkvFChtLk%3D 10435596
115. JS Smith I Tachibana SM Passe BK Huntley TJ Borell N Iturria JR O'Fallon PL Schaefer BW Scheithauer CD James JC Buckner RB Jenkins 2001 PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme J Natl Cancer Inst 93 1246 1256 1:CAS:528: DC%2BD3MXms1Ortbw%3D 11504770
116. Y Sonoda T Kumabe T Nakamura R Saito M Kanamori Y Yamashita H Suzuki T Tominaga 2009 Analysis of IDH1 and IDH2 mutations in Japanese glioma patients Cancer Sci 100 1996 1998 1:CAS:528:DC%2BD1MXht12qs7bP 19765000
117. R Stupp WP Mason MJ van den Bent M Weller B Fisher MJ Taphoorn K Belanger AA Brandes C Marosi U Bogdahn J Curschmann RC Janzer SK Ludwin T Gorlia A Allgeier D Lacombe JG Cairncross E Eisenhauer RO Mirimanoff 2005 Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 987 996 1:CAS:528:DC%2BD2MXit1Wksbk%3D 15758009
118. N Sugawa AJ Ekstrand CD James VP Collins 1990 Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas Proc Natl Acad Sci USA 87 8602 8606 1:CAS:528:DyaK3MXhvVKntQ%3D%3D 2236070
119. L Tentori C Leonetti M Scarsella G D'Amati M Vergati I Portarena W Xu V Kalish G Zupi J Zhang G Graziani 2003 Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma Clin Cancer Res 9 5370 5379 1:CAS:528:DC%2BD3sXovVOnsrY%3D 14614022
120. Toedt G, Barbus S, Wolter M, Felsberg J, Tews B, Blond F, Sabel MC, Hofmann S, Becker N, Hartmann C, Ohgaki H, von Deimling A, Wiestler OD, Hahn M, Lichter P, Reifenberger G, Radlwimmer B (2010) Molecular signatures classify astrocytic gliomas by IDH1 mutation status. Int J Cancer
121. D Trost M Ehrler R Fimmers J Felsberg MC Sabel L Kirsch J Schramm OD Wiestler G Reifenberger RG Weber 2007 Identification of genomic aberrations associated with shorter overall survival in patients with oligodendroglial tumors Int J Cancer 120 2368 2376 1:CAS:528:DC%2BD2sXksFSktbo%3D 17285580
122. MJ van den Bent AF Carpentier AA Brandes M Sanson MJ Taphoorn HJ Bernsen M Frenay CC Tijssen W Grisold L Sipos H Haaxma-Reiche JM Kros MC van Kouwenhoven CJ Vecht A Allgeier D Lacombe T Gorlia 2006 Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial J Clin Oncol 24 2715 2722 16782911
123. MJ van den Bent HJ Dubbink Y Marie AA Brandes MJ Taphoorn P Wesseling M Frenay CC Tijssen D Lacombe A Idbaih R van Marion JM Kros WN Dinjens T Gorlia M Sanson 2010 IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group Clin Cancer Res 16 1597 1604 20160062
124. MJ van den Bent HJ Dubbink M Sanson CR van der Lee-Haarloo M Hegi JW Jeuken A Ibdaih AA Brandes MJ Taphoorn M Frenay D Lacombe T Gorlia WN Dinjens JM Kros 2009 MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951 J Clin Oncol 27 5881 5886 19901104
125. MJ van den Bent LH Looijenga K Langenberg W Dinjens W Graveland L Uytdewilligen PA Sillevis Smitt RB Jenkins JM Kros 2003 Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features Cancer 97 1276 1284 12599236
126. RG Verhaak KA Hoadley E Purdom V Wang Y Qi MD Wilkerson CR Miller L Ding T Golub JP Mesirov G Alexe M Lawrence M O'Kelly P Tamayo BA Weir S Gabriel W Winckler S Gupta L Jakkula HS Feiler JG Hodgson CD James JN Sarkaria C Brennan A Kahn PT Spellman RK Wilson TP Speed JW Gray M Meyerson G Getz CM Perou DN Hayes 2010 Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1 Cancer Cell 17 98 110 1:CAS:528:DC%2BC3cXkvFKgsL4%3D 20129251
127. I Vlassenbroeck S Califice AC Diserens E Migliavacca J Straub I Di Stefano F Moreau MF Hamou I Renard M Delorenzi B Flamion J DiGuiseppi K Bierau ME Hegi 2008 Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma J Mol Diagn 10 332 337 1:CAS:528:DC%2BD1cXpt1eitr8%3D 18556773
128. PS Ward J Patel DR Wise O Abdel-Wahab BD Bennett HA Coller JR Cross VR Fantin CV Hedvat AE Perl JD Rabinowitz M Carroll SM Su KA Sharp RL Levine CB Thompson 2010 The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α-ketoglutarate to 2-hydroxyglutarate Cancer Cell 17 225 234 1:CAS:528:DC%2BC3cXlsVWqtLg%3D 20171147
129. T Watanabe S Nobusawa P Kleihues H Ohgaki 2009 IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas Am J Pathol 174 1149 1153 1:CAS:528:DC%2BD1MXksVOksLY%3D 19246647
130. T Watanabe A Vital S Nobusawa P Kleihues H Ohgaki 2009 Selective acquisition of IDH1 R132C mutations in astrocytomas associated with Li-Fraumeni syndrome Acta Neuropathol 117 653 656 1:CAS:528:DC%2BD1MXlvFOksb8%3D 19340432
131. M Weller H Berger C Hartmann J Schramm M Westphal M Simon R Goldbrunner D Krex JP Steinbach CB Ostertag M Loeffler T Pietsch A von Deimling 2007 Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker? Clin Cancer Res 13 6933 6937 1:CAS:528:DC%2BD2sXhtlyit7fL 18056167
132. M Weller J Felsberg C Hartmann H Berger JP Steinbach J Schramm M Westphal G Schackert M Simon JC Tonn O Heese D Krex G Nikkhah T Pietsch O Wiestler G Reifenberger A von Deimling M Loeffler 2009 Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network J Clin Oncol 27 5743 5750 1:CAS:528:DC%2BC3cXhtVWisbg%3D 19805672
133. M Weller R Stupp G Reifenberger AA Brandes MJ van den Bent W Wick ME Hegi 2010 MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol 6 39 51 1:CAS:528:DC%2BC3cXisV2gtA%3D%3D 19997073
134. SA Weppler Y Li L Dubois N Lieuwes B Jutten P Lambin BG Wouters G Lammering 2007 Expression of EGFR variant vIII promotes both radiation resistance and hypoxia tolerance Radiother Oncol 83 333 339 1:CAS:528: DC%2BD2sXmsFKhsbw%3D 17512071
135. W Wick C Hartmann C Engel M Stoffels J Felsberg F Stockhammer MC Sabel S Koeppen R Ketter R Meyermann M Rapp C Meisner RD Kortmann T Pietsch OD Wiestler U Ernemann M Bamberg G Reifenberger A von Deimling M Weller 2009 NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide J Clin Oncol 27 5874 5880 1:CAS:528:DC%2BC3cXhtVWis7g%3D 19901110
136. CJ Wikstrand LP Hale SK Batra ML Hill PA Humphrey SN Kurpad RE McLendon D Moscatello CN Pegram CJ Reist, et al. 1995 Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas Cancer Res 55 3140 3148 1:CAS:528:DyaK2MXmvVyitLo%3D 7606735
137. H Yan DW Parsons G Jin R McLendon BA Rasheed W Yuan I Kos I Batinic-Haberle S Jones GJ Riggins H Friedman A Friedman D Reardon J Herndon KW Kinzler VE Velculescu B Vogelstein DD Bigner 2009 IDH1 and IDH2 mutations in gliomas N Engl J Med 360 765 773 1:CAS:528:DC%2BD1MXitFWru7o%3D 19228619
138. S Yip AJ Iafrate DN Louis 2008 Molecular diagnostic testing in malignant gliomas: a practical update on predictive markers J Neuropathol Exp Neurol 67 1 15 1:CAS:528:DC%2BD1cXhtlyjurY%3D 18091559
139. S Yip J Miao DP Cahill AJ Iafrate K Aldape CL Nutt DN Louis 2009 MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance Clin Cancer Res 15 4622 4629 1:CAS:528: DC%2BD1MXosV2ltL8%3D 19584161
140. K Yoshimoto J Dang S Zhu D Nathanson T Huang R Dumont DB Seligson WH Yong Z Xiong N Rao H Winther A Chakravarti DD Bigner IK Mellinghoff S Horvath WK Cavenee TF Cloughesy PS Mischel 2008 Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples Clin Cancer Res 14 488 493 1:CAS:528:DC%2BD1cXhtVKiu7c%3D 18223223
141. S Zhao Y Lin W Xu W Jiang Z Zha P Wang W Yu Z Li L Gong Y Peng J Ding Q Lei KL Guan Y Xiong 2009 Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1α Science 324 261 265 1:CAS:528:DC%2BD1MXktFals7g%3D 19359588